Copyright investors
Eli Lilly (LLY) stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 70 to 77. This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database. Over 100 years of market history shows that the market's biggest winners tend to have an RS Rating of above 80 in the early stages of their moves. See if Eli Lilly stock can continue to show renewed price strength and hit that benchmark. Is Eli Lilly Stock A Buy? Eli Lilly stock has been rallying despite the market selloff Tuesday, a good sign. It's working on a consolidation with a 972.53 entry. See if the medical stock can break out in volume at least 40% above average. Earnings grew 495% last quarter, up from 61% in the prior report. Revenue also increased, from 38% to 54%. Eli Lilly stock holds the No. 1 rank among its peers in the Medical-Diversified industry group. GSK ADR (GSK) and AstraZeneca ADR (AZN) are also among the group's highest-rated stocks. This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article. YOU MAY ALSO LIKE
